Interestingly, several peptides with different degrees of co-agonism for the glucagon and GLP-1 receptors were recently discovered [35], and are currently in clinical evaluation for the treatment of obesity and diabetes [115,118]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.